Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops 3rd GBHI conference – all speakers confirmed 1st GBHI-Conference – Conference Report now available Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
PAES Feasibility EMA Oncological patients ANVISA Pharmacology Consultancy SDV Eye disease Data Validation Plan Standardisation IMPD Project Management Asthma Ophthalmology Phase I Unit Pragmatism DDI Inspection NIS Monitoring Central surveillance system ICF DUS Efficacy Auditing Source Data Verification Legal representative Common cold Macular Competence PASS Non interventional DFI DPI Endpoint Ophthalmologist Statistical services Drug Drug Interaction Lung Scientific advice Metered dose inhaler In vitro in vivo correlation Patients Referral system Paediatricians Life cycle management Patient recruitment SOP based Quality Assurance Investigators brochure Slit lamp microscopy Absorption Database Phase I Sequential designs GLP ADAM Cardiovascular surveillance IB Phase II Hypothalamic Gynaecological trials Pulse oximetry plethysmography Clinical study Early phase CRO Allergy Spacious archive Uveitis CDSIC Dose linearity Biopharmaceutics AGAH MMM CRF CDISC Xerostomia Charcoal Clinical trials Scientific expertise Axis Biopharmaceutical Standard operating procedure CRA Authorities Protocol development Bioequivalence FDA Phase IV US CFR 21 Part 11 Degeneration Phase III Drug Food Interaction Ocular tolerability TTS HRT Absorption windows SocraTec C&S Oncologic network Cough OTC Good Clinical Practice Pharmacokinetics Post authorisation Pilot study Network Inhalatives Steady state Quality CDM Pharmacokintetics GCP training Patch Clinical pharmacology unit Contraception Creativity Pituitary Postmenopausal women Clinical Monitoring Sample size estimation Protocol Training Dermal irritation Immunogenicity Anaesthesiologist Statistical programming FIM Healthy subjects Quality Management System Female adolescents Phase IIa trials Safety Audit Recruitment rates Ovulation inhibition Sore throat SAS Informed Consent Procedure Transdermal therapeutic system First in human CDASH Highly variable drugs Design development Thuringia WinNonlin Pharmacodynamic studies Biometrics Phase IIb trials Data Management Plan Ophthalmological trials Patch adhesion Edema Elpro Oncology Centralised procedure Expert Subcontractor qualification Adrenocortical Product development Rhine Main area Statistical Analysis Plan Copyright Legal Information Dry powder inhaler GCP COPD IVIVC HTA IEC Intensive assessment station Children Glaucoma Hormone replacement therapy HPA axis MCID Clinical development program Local tolerability Dry eye Biosimilars Sensitisation trials Experience Bioavailability Data management US FDA MDI  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page